16 July 2015
Good Timing Critical to Maximising Milking Cow Performance
MILTON KEYNES, UK, July 16 2015 – Adapting milking parlour routines to ensure optimum timing for cluster attachment could help many dairy herds increase milk yields, achieve faster milking times and reduce the risks of mastitis.
This was the view of Synergy Farm Health dairy vet Alastair Hayton, speaking at a Livestock Event seminar sponsored by MSD Animal Health (known as Merck Animal Health in the United States and Canada), who said a 60-90 second time period from first udder contact to cluster attachment was critical to optimal milking performance.
“The cow requires a physical stimulus, gained from the teats being handled during teat preparation, in order to release oxytocin, the hormone that triggers milk letdown,” he explained, “and the process from stimulus to milk flow is not instantaneous.
“If clusters are attached outside the optimum 60-90 second time period, something called bimodal milk flow can occur and this will result in reduced yields, a slower overall milking time and potential damage to teat ends that can ultimately mean a greater risk of mastitis.”
Where sub-optimal performance in relation to clinical and sub-clinical mastitis and milk quality linked to parlour performance is occurring, Mr Hayton recommended a ‘gold standard’ pre-milking routine of strip, dip, dry and apply. He said that the routine should also ensure optimum timing between first stimulus and cluster attachment.
“There is plenty of contention around the value of fore-milking, and varying views on wet and dry teat wiping and the merits of pre-dipping,” he said, “and different approaches will suit different herd and parlour situations. However, avoiding the consequences of bimodal milking by ensuring the right timing of cluster attachment is an area where many herds could see benefits.”
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to theScience of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site.